Mesoblast's shares rallied ahead of the bell Friday after the Australian regenerative medicine company disclosed initial sales of Ryoncil, its recently launched mesenchymal stromal cell therapy for ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

US FDA 200+CRLs to help pharma industry engage in a more transparent manner: Experts: Shardul Nautiyal, Mumbai Friday, July 18, 2025, 08:00 Hrs [IST] US FDA 200+Complete Response ...

GSK (GSK) stock slips as FDA advisors vote against the approval of a combination regimen involving thecompany's blood cancer drug Blenrep. Read more here.

George Mulligan, PhD, previews the FDA's ODAC meeting discussing the application of belantamab mafodotin-based combinations for the treatment of multiple myeloma.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales ...

Kerstin Wolff of Maiwald Intellectual Property examines the EU’s winding path towards the regulation of new genomic ...

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications <li ...